Review
Copyright ©2009 Baishideng.
World J Gastrointest Oncol. Oct 15, 2009; 1(1): 47-54
Published online Oct 15, 2009. doi: 10.4251/wjgo.v1.i1.47
Table 1 Grade 3/4 side effects in active regimens for advanced gastric cancer
FAMTXECFEOXCFDCFS1CS
Anemia108.0-13.18.626184.0-12.826
Thrombocytopenia84.0-4.75.21380.0-1.35
Neutropenia5836.0-41.727.657825.6-11.040
Febrile neutropenia208.0-9.37.812290.0-1.03
Diarrhea72.6-6.011.98193.0-7.74
Stomatitis1.32.227210.01
Hand-foot syndrome13.0-4.33.10.00
Nausea and vomitting510.2-17.011.417141.0-5.611 and 4
Peripheral neuropathy0.44.4382.00
Lethargy16.624.914192.0-5.14
Alopecia14244.2-56.028.8
Increased creatinine31.00.00
Ref.[8][8,9][9][12][12][16,17][16]
Table 2 Phase III milestone trials of chemotherapy for far advanced gastric cancer and information of the elderly patients
PublicationTrialRegimensOS (number)Selected regimensMedianAge rangeProportion of elderly patients (70 years old or over)Ref.Country
1991EORTC5-FU/Adriamycin/MMC (FAM)4 (79)FAMTX5823-69No information[7]EORTC
5-FU/Adriamycin/Methotrexate (FAMTX)6 (81)5728-77
1993Murad et alFAMTX9 (30)FAMTX5826-72No information[3]Brazil
Best supportive care (BSC)3 (10)5730-71
1995Pyrhönen et al5-FU/Epirubicin/Methotrexate (FEMTX)12.3 (21)FEMTX5842-75No information[5]Finland
BSC3.1 (20)5842-71
1997Glimelius et al5-FU/Leucovorin/Etoposide (FLE)8 (31)ELF6445-75No information[4]Sweden
BSC5 (31)6340-74
1997Webb et alEPI/CDDP/5-FU (ECF)8.9 (111)ECF5935-79No information[8]UK
FAMTX5.7 (108)6029-78
2000Vanhoefer et alFAMTX6.7 (133)Similar efficacy5830-74No information[44]EORTC
ELF7.2 (132)5925-74
5-FU/CDDP (FUP)7.2 (134)5724-74
2003JCOG92055-FU7.1 (105)5-FU6327-75No information[14]Japan
5-FU/CDDP (CF)7.3 (105)6319-75
UFT/MMC6 (70)60.530-75
2006V325Docetaxel/CDDP/5-FU (DCF)9.2 (227)DCF5526-7924%-25%1[10]USA
CDDP/5-FU (CF)8.6 (230)5525-76
2007JCOG9912S111.4 (234)S16439-75No information[17]Japan
5-FU10.8 (234)6324-75
CPT11/Docetaxel12.3 (236)6332-75
2008SPIRITSS111 (150)S1/CDDP6228-7417%[18]Japan
S1/CDDP (CS)13 (148)6233-74
2008REAL-2EPI/CDDP/capecitabine (ECX)9.9 (241)EOX6425-82No information[9]UK
ECF9.9 (249)6522-83
EPI/oxaliplatin/capecitabine (EOX)11.2 (239)6225-80
EPI/oxaliplatin/5-FU (EOF)9.3 (235)6133-78
2008Al-Batran et al5-FU/LV/Oxaliplatin (FLO)10.7 (112)FLO6433-8641%-45%2[23]AIO
5-FU/LV/CDDP (FLP)8.8 (108)6427-85
Table 3 Phase III milestone trials of adjuvant therapy for gastric cancer after surgical resection and information of elderly patients
PublicationTrialsPatient eligibilitySuccessful regimens as adjuvant therapyAdjuvant effectMedianRangeProportion of elderly patients (70 years old or over)Ref.Country
2001INT-116Pathological stage IB/II/III/IVM0Surgery + Chemo (5-FU/LV)-Radiation (45Gy)9% at 3 years6025-87No information[31]USA
Surgery alone5923-80
2006MAGICClinical stage II or more (M0)Surgery + perioperative EPI/CDDP/5-FU (ECF)13.6% at 5 years6229-8520.4%[32]UK
Surgery alone6223-8121.3%
2007ACTS-GCPathological stage II/IIIA/IIIBSurgery + S110% at 3 years6327-8025.9%[34]Japan
Surgery alone6333-8022.6%